Johnson & Johnson $JNJ Shares Purchased by Vident Advisory LLC

Key Points

• Vident Advisory LLC has increased its stake in Johnson & Johnson by 4.1%, owning a total of 148,165 shares valued at approximately $24.57 million.
• Johnson & Johnson reported a strong earnings quarter with $2.77 EPS, exceeding estimates, along with $23.74 billion in revenue and a year-over-year revenue growth of 5.8%.
• The company announced a quarterly dividend of $1.30 per share, yielding 3.0%, with a current payout ratio of 55.61%.

Vident Advisory LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 148,165 shares of the company's stock after acquiring an additional 5,870 shares during the period. Vident Advisory LLC's holdings in Johnson & Johnson were worth $24,573,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Elios Financial Group Inc. lifted its position in Johnson & Johnson by 1.5% in the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after purchasing an additional 66 shares during the period. Atlantic Family Wealth LLC lifted its position in Johnson & Johnson by 4.4% in the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock worth $266,000 after purchasing an additional 67 shares during the period. MBA Advisors LLC lifted its position in Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after purchasing an additional 68 shares during the period. Sovereign Financial Group Inc. lifted its position in Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock worth $651,000 after purchasing an additional 69 shares during the period. Finally, Nabity Jensen Investment Management Inc lifted its position in Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after purchasing an additional 69 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $175.50 on Friday. The stock has a market cap of $422.67 billion, a PE ratio of 18.77, a price-to-earnings-growth ratio of 2.25 and a beta of 0.41. The business has a fifty day simple moving average of $165.45 and a 200-day simple moving average of $159.86. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on JNJ shares. UBS Group raised their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research note on Thursday, July 17th. Barclays raised their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Citigroup raised their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research note on Thursday, August 21st. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Guggenheim reissued a "neutral" rating and set a $167.00 price objective (up from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.